A prospective, multicentre, observational, postmarketing surveillance study of tafluprost/timolol in patients with glaucoma and ocular hypertension

Trial Profile

A prospective, multicentre, observational, postmarketing surveillance study of tafluprost/timolol in patients with glaucoma and ocular hypertension

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2016

At a glance

  • Drugs Tafluprost/timolol (Primary)
  • Indications Glaucoma; Ocular hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Dec 2016 New trial record
    • 01 Dec 2016 Interim results (n=439) from 3-months follow-up published in the Ophthalmology and Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top